Exablate has FDA approval for the pain palliation of metastatic bone cancer in patients for whom radiation therapy is not an alternative and CE Mark for pain palliation of painful bone metastases and local treatment of cancerous and benign primary and secondary bone tumors.
In the US, Exablate is approved for the following applications: .